| scholarly article | Q13442814 |
| P2093 | author name string | Javier Cortes | |
| Jose Perez-Garcia | |||
| Esther Holgado | |||
| Maria Gion | |||
| P2860 | cites work | Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. | Q40521722 |
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial | Q43951696 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice | Q47736637 | ||
| Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). | Q47782850 | ||
| Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. | Q50908445 | ||
| Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. | Q51022930 | ||
| First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. | Q51170722 | ||
| Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. | Q52907227 | ||
| Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 | Q62604205 | ||
| Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 | ||
| Conditionally reprogrammed pancreatic cancer cells: A novel patient-derived cell line model for human pancreatic cancer studies | Q90068935 | ||
| Cancer genome landscapes | Q22242276 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy | Q28235277 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. | Q35102480 | ||
| Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer | Q36064908 | ||
| Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer | Q36463604 | ||
| Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. | Q37166436 | ||
| Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy | Q37194864 | ||
| Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer | Q38126859 | ||
| Targeting HER2 for the treatment of breast cancer | Q38317974 | ||
| Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study | Q38376822 | ||
| Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial | Q38407917 | ||
| The genomic landscape of breast cancer and its interaction with host immunity | Q38915694 | ||
| Immunogenic cell death in cancer and infectious disease | Q38982422 | ||
| Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 | ||
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 21 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | NPJ Breast Cancer | Q27727120 |
| P1476 | title | Is there a role for immunotherapy in HER2-positive breast cancer? | |
| P478 | volume | 4 |
| Q91272277 | Clinicopathological values of PD-L1 expression in HER2-positive breast cancer |
| Q90009685 | Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment |
| Q92416882 | Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity |
| Q90644277 | Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer |
Search more.